2017
DOI: 10.1159/000479407
|View full text |Cite
|
Sign up to set email alerts
|

Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy

Abstract: Background/Aims: Adult cardiomyocytes can re-enter cell cycle as stimulated by prohypertrophic factors although they withdraw from cell cycle soon after birth. p21WAF1/CIP1, a cyclin-dependent kinase inhibitor, has been implicated in cardiac hypertrophy, however, its precise contribution to this process remains largely unclear. Methods: The gene expression profile in left ventricle (LV) of spontaneously hypertensive rats (SHR) and Wistar–Kyoto (WKY) rats was determined using quantitative PCR array a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 41 publications
(63 reference statements)
0
6
0
Order By: Relevance
“…The samples from liver were processed and western blot analysis was performed as reported (Tong et al, 2017 ). Primary antibodies, including anti-Complex I (0.5μg/ml Santa Cruz Biotechnology, Inc., USA), anti-Complex II (0.4 μg/ml, Santa Cruz Biotechnology, Inc., USA), anti-Complex III (1.25 μg/ml, Abcam, Cambridge, MA, USA), anti-Complex IV (1 μg/ml, Invitrogen, Carlsbad, CA, USA), and anti-Complex V (1 μg/ml, Abcam, Cambridge, MA, USA) antibody were used.…”
Section: Methodsmentioning
confidence: 99%
“…The samples from liver were processed and western blot analysis was performed as reported (Tong et al, 2017 ). Primary antibodies, including anti-Complex I (0.5μg/ml Santa Cruz Biotechnology, Inc., USA), anti-Complex II (0.4 μg/ml, Santa Cruz Biotechnology, Inc., USA), anti-Complex III (1.25 μg/ml, Abcam, Cambridge, MA, USA), anti-Complex IV (1 μg/ml, Invitrogen, Carlsbad, CA, USA), and anti-Complex V (1 μg/ml, Abcam, Cambridge, MA, USA) antibody were used.…”
Section: Methodsmentioning
confidence: 99%
“…In different animal models of cardiac hypertrophy, the expression changes of p21 are inconsistent, and so are the corresponding effects. In Angiotensin II-mediated cardiac hypertrophy, p21 expression level is reduced, but in a variety of other cardiac hypertrophy models, such as spontaneously hypertensive rats and isoproterenol stimulation, p21 expression is continuously increased 6,7 . The expression of p21 in doxorubicin-induced cardiotoxicity is similar to that of cardiac hypertrophy and has its two sides 8,9 .…”
Section: Introductionmentioning
confidence: 99%
“…p21, a key regulator of tumor proliferation [34], can arrest most G1-phase in response to various stimuli [27], which is indispensable for cell-cycle progression. Various genes could promote the tumor proliferation and progression by inhibiting p21 [28, 29]. Moreover, it’s been reported that NDRG1 could up-regulate p21 protein expression.…”
Section: Resultsmentioning
confidence: 99%
“…p21, the inhibitor of the cyclin-dependent kinase and effector of the p53 tumor suppressor, is indispensable for cell-cycle progression, which can arrest most G1-phase in response to various stimuli [27]. Various genes could promote the tumor proliferation and progression by inhibiting p21 [28, 29]. In addition, there are studies suggesting that loss expression and/or function of p21 may contribute to tumorigenesis and metastasis [27, 30].…”
Section: Introductionmentioning
confidence: 99%